ArticlePloS one2026
Global, regional, and national burden of soft tissue and other extraosseous sarcomas, 1990-2021: A Systematic analysis for the global burden of disease study 2021.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSoft tissue and other extraosseous sarcomas (STOES) are rare malignancies originating from mesenchymal tissues, posing a substantial health burden due to their aggressiveness and complex treatment. Understanding the global, regional, and national burden of STOES is crucial for effective prevention, screening, treatment, and resource allocation.
methodsUsing the standardized Global Burden of Disease (GBD) methodology, we calculated STOES incidence, prevalence, mortality, and disability-adjusted life years (DALYs) to derive the burden of disease caused by STOES. Results were presented in numerical counts and age-standardized rates per 100,000 population, with an uncertainty interval (UI) to highlight potential statistical variability. The Joinpoint regression analysis was used to analyze the time trend from 1990 to 2021. The method facilitates the calculation of annual percentage change (APC) and average annual percentage change (AAPC) and their corresponding 95% confidence intervals (CI).
resultsIn 2021, the global burden of STOES remained substantial with 96,201 incident cases (ASIR: 1.16 per 100,000), 480,473 prevalent cases, 50,203 deaths (ASMR: 0.6 per 100,000), and 1,677,891 DALYs. Males had higher incidence, prevalence, mortality, and DALY rates than females. Regional disparities were evident, with high-income regions exhibiting higher incidence and prevalence but lower mortality rates compared to low-income regions. Notably, East Asia and Oceania had the lowest incidence rates, while Eastern Sub-Saharan Africa had the highest mortality and DALY rates. A mild downward trend was observed in incidence and prevalence, with more pronounced declines in mortality and DALY rates.
conclusionDespite declining trends, the global burden of STOES remains significant, with notable regional differences. Tailored prevention, early detection, and treatment strategies, along with targeted resource allocation, are crucial. Further research is needed to understand the underlying factors driving these trends and develop effective interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.